Global Antithrombin Market 2025 – 2034

Reports Description

According to Custom Market Insights (CMI), The Global Antithrombin Market Size was valued at USD 642.5 Million in 2024 and is expected to reach USD 677.07 Million in 2025, and is estimated to reach USD 1089.71 Million by the end of 2034 at a CAGR of approximately 5.43% during the forecast period 2025-2034.

Antithrombin is considered a blood thinner in the human blood, which prevents it from clotting. It is a natural component contained in the human blood, which behaves as a thinner to avoid the formation of clots. It is used during surgical procedures to prevent the blood from clotting and hence maintain the normal blood flow of the individual's body. In cases where this component of antithrombin is found to be low in the body of the individual, it is externally induced during the surgical procedure to maintain the blood viscosity.

To learn more about this report - request a sample report PDF

Lack of antithrombin in the individual's body leads to multiple complications during a surgical procedure and even during the occurrence of local injuries on the individual's body. The blood flow cannot be controlled naturally by the body's system as a result of the failure of the individual's defense mechanism. Excessive blood flow occurs in such individuals, which emerges as a life-threatening condition for the person. Complicated procedures in the field of surgery, such as cardiopulmonary bypass, utilize the component of antithrombin to oxygenate the extracorporeal membrane of the organ.

The surgery procedure becomes extremely fluent and easy with the use of external antithrombin, which helps maintain the blood viscosity. Certain parameters which denote the presence of antithrombin in the individual's blood insufficiently amount help to judge the complications that can occur during the surgical procedure which will be performed on the individual. Surgeons commonly consider the laboratory examinations of antithrombin antigen and antithrombin activity to gauge the viscosity of the blood and the presence of the necessary component, the absence of which might complicate the surgical procedure.

In certain cases, the individual faces or deficiency of antithrombin as a result of inheritance which results as a genetic factor, where necessary precautions are to be taken by the individual during their entire life to prevent excessive blood loss from the body, which can be life-threatening if not monitored closely. Certain conditions have been noted that lead to the deficiency of antithrombin and are termed as an acquired deficiency that is caused due to multiple other diseases which proved to be life-threatening for the individual.

The above two conditions, which have been discussed, emerge as life-threatening risk factors that cause deficiency of antithrombin in the body of the individual and might complicate the surgical procedure, which is harmful to the patient.

The pandemic outbreak significantly impacted the growth of the antithrombin market due to the strict lockdown and restricted movement imposed by the government all over the world.

The strict rules and regulations imposed on the healthcare sector for attending to and treating patients, which hampered regular follow-ups and treatment procedures, significantly impacted the growth of the antithrombin market. These steps were taken to prevent the risk of cross-infection among the infected patients and the medical staff along with the other patients. A common complication during the pandemic, which was noted among the patients, was clotting of blood, which helped boost the antithrombin market. This component of the blood was in huge demand in the healthcare sector during the pandemic to increase the success rate and survival of the patients. The condition of the patient suffering during the pandemic got complicated greatly due to the clotting factor in the individual's body. The deficiency of antithrombin in the blood was considered a major cause of the complications during the pandemic.

Growth Factors

The rapidly increasing number of patients who suffer from deficiency of antithrombin in the blood has emerged as a major growth factor for the antithrombin market. The huge number of surgical procedures carried out worldwide, which mainly include open heart surgical procedures, have helped to boost the market for antithrombin to a great extent.

The procedures included during hemodialysis are also emerging as a major growth factor for the market. This component of the blood is a protein that is present in the body and performs a major function by preventing clots in the blood. The function of the thrombin is controlled with the help of this component that helps to maintain the viscosity of the blood during surgical procedures. This blood component is mainly produced with the help of the liver, which includes around 432 amino acids. Severe diseases that a person suffers from, such as severe trauma, nephrotic syndrome and liver failure, emerged as the major causes that lead to acquired antithrombin deficiency.

A huge number of people worldwide suffer from this type of deficiency due to the increasing number of high-velocity accidents all over the world. The use of antithrombin has increased to a great extent as a result of this deficiency that is caused in people.

Certain antigen tests are carried out on the individual's body to measure the presence of antithrombin in the blood to avoid further complications during the surgical procedure.

The huge number of people suffering from coagulation disorders has helped the market to record tremendous revenue during the forecast period. Rapidly increasing modernization worldwide has pushed people towards many unnecessary habits such as alcoholism which hampers the function of the liver and shows a tremendous impact on the production of antithrombin. The key market players have conducted extensive research and development programs to develop advanced medicines in the market to prevent the deficiency of antithrombin in the body. The hospital sector's huge number of operative procedures has made it a major market for the demand and supply of antithrombin components.

Segmental Insights

Segmentation of the antithrombin market based on Application Type

Based on application type, the therapeutics segment has evolved as the leading market player owing to its huge market share in the global economy. Demand for antithrombin in the therapeutics and healthcare sector has evolved as the major cause for the growth of this segment in the market. The huge number of people who suffer from antithrombin deficiencies resulting from multiple causes require using this blood component to carry out a successful operative procedure.

The increasing number of operative procedures worldwide has boosted the demand for antithrombin in the healthcare sector, mainly attributed to the operative procedure carried out in this field. A huge amount of blood loss is experienced during digital procedures, which can be fatal for the patient's life and hence needs to be controlled with the help of antithrombin. The genetic causes of antithrombin deficiency are very rare among people and are mainly attributed to acquired causes of deficiency which emerge as the major factors for the lack of this component in the blood.

A few severe disease conditions that result in the deficiency of antithrombin in the body include nephrotic syndrome, severe burns and liver failure. Huge demand for antithrombin was experienced in the healthcare sector for therapeutic application during the pandemic, which presented the clotting of blood as a major reason that resulted in the death of many patients.

• Segmentation of antithrombin market based on Source

Based on the source, the segment of goat milk has emerged as a major market due to the largest contribution it has supported the market with. The component of antithrombin, obtained from goat milk, emerges as the fastest developing segment due to the huge demand it has experienced from the healthcare sector, which experienced its efficacy in clinical trials.

The antithrombin protein obtained from goat milk has emerged to be very useful for treatment procedures and surgeries which has shown a good response worldwide. Key market players Carrying out research and development programs, making more advancements to alter the composition to make it more suitable for the body of human beings. The antithrombin components obtained from human beings also show considerable growth resulting from its extensive demand in the healthcare sector.

• Segmentation of the antithrombin market based on Dosage

Based on dosage, the segment which proves to be a potential reason for the market's growth is that of lyophilized antithrombin. The other segment that has been discussed under this category includes liquids that have been administered in the form of antithrombin.

Report Scope

Feature of the Report	Details
Market Size in 2025	USD 677.07 Million
Projected Market Size in 2034	USD 1089.71 Million
CAGR Growth Rate	5.43% CAGR
Base Year	2024
Forecast Period	2025-2034
Prominent Players	Lee Biosolutions, Scripps Laboratories, Octapharma AG, LFB USA, rEVO Biologics, Grifols, CSL Ltd, Kedrion, and Others
Key Segment	By Application Type, Source, Dosage, and Region
Report Coverage	Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope	North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options	Request tailored purchasing options to fulfil your requirements for research.

Regional Insights

Based on geography, the region of Asia Pacific has emerged as the largest consumer and fastest developing market owing to the rapid advancements that have been made in the healthcare sector. The huge number of operative procedures carried out in this region has emerged as a major factor in the market's growth.

The increasing demand for reducing the number of deaths that have taken place during surgical procedures has boosted the demand for antithrombin in the healthcare sector. Europe emerged as the next potential market for antithrombin resulting from the huge demand for human-based antithrombin among the people.

The advanced health care facilities provided to the people by the government have emerged as a major growth factor for the antithrombin market in this sector. The region of North America has also shown considerable growth owing to the rapid development and increasing number of operative procedures carried out in this region.

Recent Developments

• In February 2009, the Food and Drug Administration approved a therapeutic application under the title of ATryn. This therapeutic application was obtained genetically from the goats. This application was administered with a view to and hence blood thinning procedure in the form of antithrombin protein.
• In January 2013 – An LFB company, GTC biotherapeutics, introduced the name change to Revo biologics. The firm disclosed its future commitments to evolve recombinant medicines and drugs.

Key players

• Lee Biosolutions
• Scripps Laboratories
• Octapharma AG
• LFB USA
• rEVO Biologics
• Grifols
• CSL Ltd
• Kedrion

Segments of the antithrombin market covered in the report

By Application Type

• Research
• Therapeutics
• Diagnostics

By Source

• Goat milk
• Human

By Dosage

• Liquid
• Lyophilized

On the basis of Geography

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America